Transmembrane protein 16A/anoctamin 1 inhibitor T16A-A01 reversed monocrotaline-induced rat pulmonary arterial hypertension
Transmembrane protein 16A was involved in the development of the monocrotaline-induced pulmonary arterial hypertension model through ERK1/2 activation, and it was considered as potential target for pulmonary arterial hypertension treatment. A pulmonary arterial hypertension rat model was established...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-10-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894020946670 |